MX2010005871A - Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa. - Google Patents

Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.

Info

Publication number
MX2010005871A
MX2010005871A MX2010005871A MX2010005871A MX2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A
Authority
MX
Mexico
Prior art keywords
pseudomonas aeruginosa
antibodies
pcrv
pcrv antigen
antigen
Prior art date
Application number
MX2010005871A
Other languages
English (en)
Inventor
Christopher R Bebbington
Geoffrey T Yarranton
Kenneth Luehrsen
Mark Baer
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of MX2010005871A publication Critical patent/MX2010005871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención provee anticuerpos de alta afinidad a la proteína de PcrV de Pseudomonas aeruginosa que tienen inmunogenicidad reducida cuando son administrados para tratar infecciones de Pseudomonas aeruginosa.
MX2010005871A 2007-11-30 2008-12-01 Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa. MX2010005871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
MX2010005871A true MX2010005871A (es) 2010-06-09

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005871A MX2010005871A (es) 2007-11-30 2008-12-01 Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.

Country Status (15)

Country Link
US (3) US8044181B2 (es)
EP (1) EP2220117A2 (es)
JP (1) JP5781765B2 (es)
KR (1) KR20100097719A (es)
CN (1) CN101910197B (es)
AU (1) AU2008333985B2 (es)
BR (1) BRPI0819598A2 (es)
CA (1) CA2706732A1 (es)
EA (1) EA201000903A1 (es)
IL (1) IL206036A0 (es)
MX (1) MX2010005871A (es)
NZ (1) NZ586357A (es)
SG (1) SG186017A1 (es)
WO (1) WO2009073631A2 (es)
ZA (1) ZA201003852B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1774017B1 (en) 2004-07-26 2013-05-15 Pfenex Inc. Process for improved protein expression by strain engineering
WO2008134461A2 (en) * 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN102137870B (zh) 2008-01-10 2014-09-03 盐野义制药株式会社 抗PcrV抗体
JP2012516897A (ja) * 2009-02-04 2012-07-26 カロバイオス ファーマシューティカルズ インコーポレイティッド シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ
CN104119437A (zh) * 2009-03-11 2014-10-29 盐野义制药株式会社 具有抗绿脓杆菌作用的人源化PcrV抗体
CA2784033A1 (en) * 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
LT2776065T (lt) * 2011-11-07 2020-10-12 Medimmune Limited Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
BR112017023378A2 (pt) * 2015-05-01 2018-07-24 Inhibrx Lp moléculas de direcionamento do sistema de secreção do tipo iii
SG10201912410TA (en) 2015-07-16 2020-02-27 Inhibrx Inc Multivalent and multispecific dr5-binding fusion proteins
CN110072554A (zh) * 2016-05-05 2019-07-30 宾夕法尼亚大学理事会 用于抗铜绿假单胞菌的dna抗体构建体
BR112021001683A2 (pt) * 2018-08-01 2021-05-04 Cephalon, Inc. anticorpos anti-cxcr2 e usos dos mesmos
BR112021023335A2 (pt) * 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225552A (en) * 1880-03-16 Disintegrating-mill
US108565A (en) * 1870-10-25 Improvement in snow-plows
US134098A (en) * 1872-12-17 Improvement in gage-cocks
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6309651B1 (en) * 1998-11-25 2001-10-30 Mcw Research Foundation Method of and compositions for immunization with the pseudomonas V antigen
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
WO2001064749A2 (en) 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DE60216564T2 (de) * 2001-01-26 2007-10-11 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
ATE458006T1 (de) * 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
CA2553692C (en) * 2004-01-20 2014-10-07 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
PT2343380T (pt) * 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
US20090215165A1 (en) 2005-05-20 2009-08-27 James Rance High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CA2613691A1 (en) 2005-07-05 2007-01-11 Baker Medical Research Institute Anticoagulation agent and uses thereof
WO2007096396A2 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
ES2405618T3 (es) 2006-06-21 2013-05-31 Oncotherapy Science, Inc. Anticuerpos monoclonales dirigidos a tumores para FZD10 y usos de los mismos

Also Published As

Publication number Publication date
ZA201003852B (en) 2014-11-26
JP5781765B2 (ja) 2015-09-24
US20120020986A1 (en) 2012-01-26
EA201000903A1 (ru) 2011-02-28
US8044181B2 (en) 2011-10-25
CN101910197A (zh) 2010-12-08
WO2009073631A3 (en) 2009-09-24
AU2008333985B2 (en) 2015-02-05
NZ586357A (en) 2012-10-26
AU2008333985A1 (en) 2009-06-11
IL206036A0 (en) 2010-11-30
CN101910197B (zh) 2014-09-24
CA2706732A1 (en) 2009-06-11
US20090191186A1 (en) 2009-07-30
KR20100097719A (ko) 2010-09-03
BRPI0819598A2 (pt) 2017-05-09
WO2009073631A2 (en) 2009-06-11
JP2011505381A (ja) 2011-02-24
EP2220117A2 (en) 2010-08-25
US20150030614A1 (en) 2015-01-29
SG186017A1 (en) 2012-12-28
US8877191B2 (en) 2014-11-04

Similar Documents

Publication Publication Date Title
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA111818C2 (uk) Антитіло проти csf-1r
WO2009112245A9 (en) Antibody against the csf-1 r
UA92505C2 (ru) Композиции на основе антитела против cd3
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
AU2016219704A1 (en) Anti-Notch1 antibodies
MX2010003574A (es) Anticuerpos il-23.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CA2883095C (en) Antibody and protein formulations
EP3702372A3 (en) Anti-cd40 human antibodies
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap

Legal Events

Date Code Title Description
FG Grant or registration